AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-11. (Canceled)

12. (Currently Amended) A tricyclic derivative represented by the following <Formula 1> or pharmaceutically acceptable salts thereof:

<Formula 1>



wherein

(1) R_1 is $-T_1-B_1$;

wherein

T_1 is ~~$-X_1-$, $-X_1-C(X_2)-$, $-N(R_5)-$,~~ $-N(R_5)C(X_2)-$, ~~$-N(R_5)S(O)n_1-$, $-N(R_5)C(O)-X_1-$ or $-N(R_5)C(X_1)NH-$,~~

~~wherein~~

~~X_1 and~~ X_2 is ~~are~~ ~~O or S; and~~

R_5 is H or C_1 ~ C_5 alkyl group~~, n_1 is an integer of 1~2~~; and

B_1 is selected from the group consisting of







[[,]] [[,]]



[[,]]



[[,]] [[,]]



[[,]]



[[,]]



[[,]]- ~~and~~



wherein,

R_6 is halogen, hydroxy, C_1-C_3 alkoxy, amino, nitro, cyano or C_1-C_3 lower alkyl group;

R_8 is H, halogen, hydroxy, C_1-C_3 alkoxy, amino, nitro, cyano or C_1-C_3 lower alkyl group;

R_7 ~~and R_9 are each~~ is halogen, hydroxyl, mercapto, -ONO, ONO_2 or SNO~~, in which R_7 and R_9 are same or different~~;



is selected from the group consisting of



C1 , C7 , C11 , and C12

wherein, C1 (pyridyl group) substituted at position 2 and 6 or position 2 and 5, C7 (pyrrolyl group) substituted at position 2 and 5 or position 2 and 4, C11 (thiophenyl group) and C12 (furanyl group) ~~a C_5-C_6-membered saturated or unsaturated heterocyclic ring containing 1-2 of hetero atom, in which the hetero atom is selected from a group consisting of O, S and N~~;

Z_1 is C_1-C_{10} straight-chain or branched-chain alkyl group;

~~Z_2 and Z_3 are each independently H or methyl group, in which Z_3 is H when Z_2 is methyl group, Z_2 is H when Z_3 is methyl group;~~

T_2 is ~~$-X_1-$ or~~ $-X_1-C(X_2)-$, in that X_1 and X_2 are each independently O ~~or S~~;

B_2 is selected from the group consisting of:



(a) [[,]] (b) [[,]]

(c) , (d) [[,]]

(e) [[,]] and ;

n_2 is an integer of 0-3; and

n_3 is an integer of 1-5;

~~n_4 is an integer of 1-5; and~~

~~n_5 and n_6 are each independently an integer of 1-6;~~

(2) R_2 and R_3 are each independently H, $-PO_3H_2$, phosphonate, sulfate, C_3-C_7 cycloalkyl, C_2-C_7 alkenyl, C_2-C_7 alkynyl, C_1-C_7 alkanoyl, C_1-C_7 straight-chain or branched-chain alkyl or sugar, in which sugar is a monosaccharide such as glucuronyl, glucosyl or galactosyl;

(3) R_4 is OCH_3, SCH_3 or $NR_{10}R_{11}$, in which R_{10} and R_{11} are each independently H or C_{1-5} alkyl; and

(4) X is O or S.

13. (Currently Amended) The tricyclic derivative or pharmaceutically acceptable salts thereof as set forth in claim 12, wherein

~~T_1 is $N(R_5)C(X_2)$-, $N(R_5)C(O)X_1$- or $N(R_5)C(X_1)NH$-, wherein X_1 and X_2 are each O,~~

~~n_4 is an integer of 1-3;~~

~~n_5 and n_6 are each independently an integer of 1~3;~~

R_2 and R_3 are each independently C_3-C_7 cycloalkyl or C_1-C_7 alkyl; and

R_4 is SCH_3 or OCH_3.

14-15. (Canceled)

16. (Previously Presented) The tricyclic derivative or pharmaceutically acceptable salts thereof as set forth in claim 12, wherein Z_1 is C_2 ~ C_5 straight-chain or branched-chain alkyl group or cycloalkyl group having substituent.

17. (Previously Presented) A tricyclic derivative or pharmaceutically acceptable salts thereof, wherein the tricyclic derivative comprises:

1)

6-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen -7-yl]-nicotineamide;

2) 5-nitrooxymethyl-furan-2-carboxylic acid-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

5) 6-nitrooxymethyl-pyridine-2-carboxylic acid-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

6) 5-nitrooxymethyl-thiophene-2-carboxylic acid-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;

8) N-[(7S)-3-ethoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-2-fluoro-3-nitrooxymethyl-benzamide;

9) 2-fluoro-N-[(7S)-3-isopropoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-3-nitrooxymethyl-benzamide;

10) 2-fluoro-3-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

11) N-[(7S)-3-cyclopentyloxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-2-fluoro-3-nitrooxymethyl-benzamide;

12) 3-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

13) N-[(7S)-3-ethoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-3-fluoro-5-nitrooxymethyl-benzamide;

14) 3-fluoro-N-[(7S)-3-isopropoxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-5-nitrooxymethyl-benzamide;

15) N-[(7S)-3-cyclopentyloxy-1,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-3-fluoro-5-nitrooxymethyl-benzamide;

16) 4-fluoro-3-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

17)
2-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;
18)
3-hydroxy-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;
19)
3,5-*bis*-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;
20)
2-hydroxy-4-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;
21) 4-nitrooxymethyl-thiophene-2-carboxylic acid
[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;
22) 3-nitrooxymethyl-thiophene-2-carboxylic acid
[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;
25) 3-nitrooxybenzoic
acid-5-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;
26) 4-nitrooxybutyric
acid-5-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;
27) 3-nitrooxymethyl-benzoic
acid-6-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;
28) 4-nitrooxybutyric
acid-6-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-methylester;

29) 3-nitrooxymethyl-benzoic acid-2-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

30) 4-nitrooxybutyric acid-2-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

31) 3-nitrooxymethyl-benzoic acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

32) 4-nitrooxybutyric acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;

33) 3-nitrooxymethyl-benzoic acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-benzylester;

34) 4-nitrooxybutyric acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-benzylester;

37) 3-fluoro-5-nitrosooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

39) 3-fluoro-5-nitrosothiomethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

40) 3-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

42) 3-fluoro-N-methyl-5-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;

43)
2-(3-fluoro-5-nitrooxymethyl-phenyl)-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide; or
44)
2-(2-fluoro-5-nitrooxymethyl-phenyl)-N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-acetamide.

18. (Previously Presented) An anticancer agent composition or anti-proliferation agent composition comprising the tricyclic derivatives or pharmaceutically acceptable salts thereof as set forth in claim 12 as an effective ingredient and a pharmaceutically acceptable excipient.

19. (Previously Presented) An angiogenesis inhibitor composition comprising the tricyclic derivatives or pharmaceutically acceptable salts thereof as set forth in claim 12 as an effective ingredient and a pharmaceutically acceptable excipient.

20. (Previously Presented) An anticancer agent composition or anti-proliferation agent composition comprising the tricyclic derivatives or pharmaceutically acceptable salts thereof as set forth in claim 17 as an effective ingredient and a pharmaceutically acceptable excipient.

21. (Previously Presented) An angiogenesis inhibitor composition comprising the tricyclic derivatives or pharmaceutically acceptable salts thereof as set forth in claim 17 as an effective ingredient and a pharmaceutically acceptable excipient.